Novartis | NOVN - Себестоимость

Биржевая цена
113.34
Изменение за день
-1.38 -1.20%
Ежемесячно
-5.41%
Ежегодный
20.84%
Q2 прогноз
111.47




Себестоимость Изменить Дата
AbbVie USD 4.22B 329M 2026-03
Alcon AG USD 1.2B 46M 2025-12
Almirall EUR 191.5M 2.29M 2025-12
Amgen USD 1.79B 128M 2025-12
AstraZeneca USD -204M 3.48B 2026-03
Autolus Therapeutics Ltd USD 25.33M 3.31M 2025-12
Bayer EUR 4.5B 194M 2025-12
Biogen USD 797.5M 302M 2026-03
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Fresenius EUR 4.45B 262M 2025-12
Fresenius Medical Care EUR 3.68B 38.37M 2025-12
Galapagos EUR 455K 84.28M 2025-12
Genmab DKK 81M 23M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 1.88B 736M 2026-03
GRIFOLS EUR 1.29B 163.12M 2025-12
Hikma Pharmaceutical USD 959M 492.5M 2025-12
J&J USD 8.07B 103M 2026-03
Lonza CHF 2.28B 189M 2025-06
Merck EUR 2.29B 183M 2025-12
Merck USD 3.32B 531M 2025-12
Novartis USD 3.54B 3M 2025-12
Novartis USD 3.54B 7M 2025-12
Novo Nordisk DKK 15.15B 2.3B 2025-12
Orion EUR 163.7M 22.9M 2026-03
Pfizer USD 6.29B 2.12B 2025-12
Philips EUR 2.81B 417M 2025-12
Recordati EUR 199.91M 20.12M 2025-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 3.67B 621M 2026-03
UCB EUR 1.07B 146M 2025-12